Publications by authors named "Biroulet L"
Article Synopsis
- - The Pharmacovigilance Risk Assessment Committee (PRAC) recommends caution when using Janus kinase inhibitors (JAKi) in older patients or those with high cardiovascular, cancer, or venous thromboembolism risks, favoring alternatives when possible.
- - A study involving 21 specialists assessed the appropriateness of JAKi through a two-round survey, finding that while initial uncertainty existed, discussions helped clarify and reduce disagreement regarding best practices.
- - The study highlights the importance of personalized patient evaluations rather than relying solely on regulatory guidelines, emphasizing active management of modifiable health risks and continued concerns over the link between JAKi and cancer risk.
